Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
- 주제(키워드) pegfilgrastim , prophylaxis , febrile neutropenia , multiple myeloma , pomalidomide
- 주제(기타) Oncology
- 설명문(일반) [Song, Ga-Young; Lee, Je-Jung; Jung, Sung-Hoon] Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, Hwasun, Jeollanamdo, South Korea; [Song, Ga-Young; Lee, Je-Jung; Jung, Sung-Hoon] Chonnam Natl Univ, Med Sch, Hwasun, Jeollanamdo, South Korea; [Moon, Joon Ho] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, Daegu, South Korea; [Kim, Dajung] Kosin Univ, Dept Internal Med, Gospel Hosp, Busan, South Korea; [Kim, Min Kyoung] Yeungnam Univ, Dept Hematol & Oncol, Med Ctr, Daegu, South Korea; [Kim, Hyo Jung] Hallym Univ, Sacred Heart Hosp, Dept Internal Med, Anyang, South Korea; [Mun, Yeung-Chul] Ewha Womans Univ, Sch Med, Div Hematol Oncol, Seoul, South Korea; [Lee, Won-Sik] Inje Univ, Busan Paik Hosp, Busan, South Korea; [Do, Young Rok] Keimyung Univ, Keimyung Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea; [Lee, Jae Hoon] Gachon Univ, Gil Med Ctr, Dept Internal Med, Incheon, South Korea; [Kim, Jin Seok] Yonsei Univ, Coll Med, Div Hematol, Severance Hosp,Dept Internal Med, Seoul, South Korea
- 등재 SCIE, SCOPUS
- OA유형 Gold Open Access; Green Published
- 발행기관 FRONTIERS MEDIA SA
- 발행년도 2023
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000213466
- 본문언어 영어
- Published As https://doi.org/10.3389/fonc.2023.1209110
- PubMed 37965454
초록/요약
IntroductionPegylated granulocyte colony-stimulating factor (G-CSF) has been widely used for preventing febrile neutropenia in various types of cancer treatment. In the present study, we prospectively evaluated the safety and efficacy of pegfilgrastim as a primary prophylaxis of febrile neutropenia and infection among patients with relapsed refractory multiple myeloma (RRMM) treated with pomalidomide-based regimens.MethodsThirty-three patients with RRMM who received pomalidomide and dexamethasone (Pd) with or without cyclophosphamide (PCd) were enrolled in this study. Twenty-eight patients were treated with PCd and 5 patients were treated with Pd. All patients were given pegfilgrastim subcutaneously with a single administration performed on the first day of each cycle as primary prophylaxis until the fourth cycle.ResultsThe median age of the patients was 75 (range 56-85), and the median prior line of therapy was 2 (range 2-6). Seventeen patients (51.5%) had any grade of neutropenia and 20 (60.6%) had any grade of thrombocytopenia before starting pomalidomide treatment. During the 4 cycles of treatment, grade 3 or more neutropenia occurred in 17 patients (51.5%), and 4 (12.1%) experienced grade 3 or more febrile neutropenia. Grade 3 or more infections occurred in 5 patients (15.2%). Interestingly, the patients with markedly increased ANC of more than 2 x 109/L compared to baseline ANC after 7 days of pegfilgrastim at 1st cycle of treatment showed a significantly lower incidence of grade 3-4 neutropenia. The most common adverse event of pegfilgrastim was fatigue, and all the adverse events caused by pegfilgrastim were grade 1 or 2. And there was no significant change in the immune cell population and cytokines during the administration of pegfilgrastim.DiscussionConsidering that this study included elderly patients with baseline neutropenia, pegylated G-CSF could be helpful to prevent severe neutropenia, febrile neutropenia, or infection in patients with RRMM.
more